Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Sean M Post, PhD, Huaxian Ma, MS, Vivian Ruvolo, Xiaorui Zhang, BS, Tomoko Yasuhiro, Kohei Tanaka, Ryohei Kozaki, Toshio Yoshizawa, PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Marina Y Konopleva, MD PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Michael Andreeff, MD PhD, Peter P. Ruvolo, PhD

Blood (2019) 134 (Supplement_1): 2550.

https://doi.org/10.1182/blood-2019-128626

Published: 2019

Journal Articles

Mertk Inhibition Promotes Anti-Leukemia Immunity By Reversing T Cell Suppression Via the PD-1 Axis

Alisa Lee-Sherick, MD, Kristen Jacobsen, PhD, Curtis J. Henry, PhD, Rebecca Parker, Xiaodong Wang, PhD, Stephen V Frye, PhD, H. Shelton Earp, MD, Deborah DeRyckere, PhD, Douglas K Graham, MD PhD

Blood (2018) 132 (Supplement 1): 4019.

https://doi.org/10.1182/blood-2018-99-119818

Published: 2018

Journal Articles

Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Myeloid Leukemia

Katherine A Minson, MD, Madeline G Huey, BA, Annie Qiu, Xiaodong Wang, PhD, Stephen V Frye, PhD, H. Shelton Earp, MD, Deborah DeRyckere, PhD, Douglas K Graham, MD PhD

Blood (2017) 130 (Supplement 1): 3823.

https://doi.org/10.1182/blood.V130.Suppl_1.3823.3823

Published: 2017

Journal Articles

Mertk Is a Therapeutic Target in Early T-Precursor Acute Lymphoblastic Leukemia

Ryan J Summers, MD, Katherine A Minson, MD, Stephen V Frye, PhD, Xiaodong Wang, PhD, H. Shelton Earp, III, MD, Deborah DeRyckere, PhD, Douglas K. Graham, MD PhD

Blood (2017) 130 (Supplement 1): 2536.

https://doi.org/10.1182/blood.V130.Suppl_1.2536.2536

Published: 2017

Journal Articles

Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia

Katherine A Minson, MD, Madeline G Huey, BS, Amanda A Hill, Irene Perez, Xiaodong Wang, PhD, Stephen Frye, PhD, H. Shelton Earp, III, MD, Deborah DeRyckere, PhD, Douglas K. Graham, MD PhD

Blood (2016) 128 (22): 2819.

https://doi.org/10.1182/blood.V128.22.2819.2819

Published: 2016

Journal Articles

Cultured Human Macrophages As a Model for Central Macrophages in Erythroblastic Islands

Esther Heideveld, MSc, Maartje van Den Biggelaar, PhD, Floris P. van Alphen, BSc, Marieke Von Lindern, PhD, Emile van den Akker, PhD

Blood (2016) 128 (22): 1248.

https://doi.org/10.1182/blood.V128.22.1248.1248

Published: 2016

Journal Articles

MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia

Lauren Shelby Page, BS, Xiaodong Wang, PhD, H. Shelton Earp, III, MD, Stephen Frye, PhD, Craig T Jordan, PhD, Alisa B. Lee-Sherick, MD

Blood (2016) 128 (22): 4044.

https://doi.org/10.1182/blood.V128.22.4044.4044

Published: 2016

Journal Articles

MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia

Katherine A Minson, MD, Catherine C Smith, MD, Alisa B. Lee-Sherick, MD, Deborah DeRyckere, PhD, Elisabeth Lasater, PhD, Amanda A. Hill, Xiaodong Wang, PhD, Stephen V. Frye, PhD, H. Shelton Earp, MD, Neil P. Shah, MD PhD, Douglas K. Graham, MD PhD

Blood (2014) 124 (21): 3757.

https://doi.org/10.1182/blood.V124.21.3757.3757

Published: 2014

Journal Articles

UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia

Deborah DeRyckere, PhD, Alisa B. Lee-Sherick, MD, Amanda A. Hill, Lauren Page, BS, Xiaodong Wang, PhD, Stephen V. Frye, PhD, H. Shelton Earp, MD, Douglas K. Graham, MD PhD

Blood (2014) 124 (21): 998.

https://doi.org/10.1182/blood.V124.21.998.998

Published: 2014

Journal Articles

MerTK-mediated engulfment of pyrenocytes by central macrophages in erythroblastic islands

Satoshi Toda, Katsumori Segawa, Shigekazu Nagata

Blood (2014) 123 (25): 3963–3971.

https://doi.org/10.1182/blood-2014-01-547976

Published: 2014

Includes: Multimedia, Supplemental data

Journal Articles

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

Susan Whitman, PhD, Jessica Kohlschmidt, PhD, Kati Maharry, MAS, Deedra Nicolet, MS, Sebastian Schwind, MD, Heiko Becker, MD, Klaus H. Metzeler, MD, Krzysztof Mrózek, MD, PhD, Jason H. Mendler, MD, PhD, Ann-Kathrin Eisfeld, MD, Stefano Volinia, PhD, Bayard L. Powell, MD, Thomas H. Carter, MD, PhD, Jonathan E. Kolitz, MD, Richard M. Stone, MD, Il-Kyoo Park, Michael A. Caligiuri, M.D., Guido Marcucci, MD, Clara D. Bloomfield, MD

Blood (2012) 120 (21): 1293.

https://doi.org/10.1182/blood.V120.21.1293.1293

Published: 2012

Journal Articles

A Small Molecule Inhibitor of the Gas6/Mer Pathway Inhibits Platelet Activation and Thrombosis with Equal Efficacy to, but Greater Potency Than, iMer, the Novel MerTK Splice Variant

Brian R. Branchford, MD, Luke Law, BS, Susan Sather, BS, Gary Brodsky, PhD, H. Shelton Earp, III, Xiaodong Wang, Stephen Frye, Douglas K. Graham, MD, PhD, Jorge A Di Paola, MD

Blood (2012) 120 (21): 3303.

https://doi.org/10.1182/blood.V120.21.3303.3303

Published: 2012

Journal Articles

A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia

Anupam Verma, MD, J. Kimble Frazer, MD, PhD, Alesia Trakhimets, William Heaton, Jared Bearrs, Steven Warner, PhD, David Bearrs, PhD, Sunil Sharma, MD

Blood (2011) 118 (21): 1519.

https://doi.org/10.1182/blood.V118.21.1519.1519

Published: 2011

Journal Articles

A Distinct Expression of Various Gene Subsets in CD34+ Cells Obtained From Patients with Early and Advanced Myelodysplastic Syndrome.

Monika Belickova, Jaroslav Cermak, M.D., Ph.D., Alzbeta Vasikova, Eva Budinska

Blood (2009) 114 (22): 3795.

https://doi.org/10.1182/blood.V114.22.3795.3795

Published: 2009

Journal Articles

A novel role for c-Src and STAT3 in apoptotic cell–mediated MerTK-dependent immunoregulation of dendritic cells

Zuoan Yi, Li Li, Glenn K. Matsushima, H. Shelton Earp, Bo Wang, Roland Tisch

Blood (2009) 114 (15): 3191–3198.

https://doi.org/10.1182/blood-2009-03-207522

Published: 2009

Includes: Supplemental data

Journal Articles

Synergistic Killing of E2A-PBX1 + B-ALL Cells by Chemotherapeutic Agents and MerTK Inhibition

Rachel M.A. Linger, Ph.D., Deborah DeRyckere, Ph.D., Luis Brandão, Ph.D., Kelly K. Sawczyn, M.D., Amy K. Keating, M.D., Douglas K. Graham, M.D., Ph.D.

Blood (2008) 112 (11): 2843.

https://doi.org/10.1182/blood.V112.11.2843.2843

Published: 2008

Journal Articles

Targeted Disruption of GAS6-Mertk Pathway Leads to Defects in Physiological Clearance of Expelled Nuclei from Erythroblasts by Bone Marrow Macrophages.

Linda Kadi, Laurent Burnier, Rocco Sugamele, Peter Carmeliet, Greg Lemke, H. Shelton Earp, Glenn K. Matsushima, Marc Schapira, Anne Angelillo-Scherrer

Blood (2007) 110 (11): 1708.

https://doi.org/10.1182/blood.V110.11.1708.1708

Published: 2007

Journal Articles

Apoptotic cells induce Mer tyrosine kinase–dependent blockade of NF-κB activation in dendritic cells

Pradip Sen, Mark A. Wallet, Zuoan Yi, Yingsu Huang, Michael Henderson, Clayton E. Mathews, H. Shelton Earp, Glenn Matsushima, Albert S. Baldwin, Jr, Roland M. Tisch

Blood (2006) 109 (2): 653–660.

https://doi.org/10.1182/blood-2006-04-017368

Published: 2006

Includes: Supplemental data

NARROW

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Mertk Inhibition Promotes Anti-Leukemia Immunity By Reversing T Cell Suppression Via the PD-1 Axis

Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Myeloid Leukemia

Mertk Is a Therapeutic Target in Early T-Precursor Acute Lymphoblastic Leukemia

Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia

Cultured Human Macrophages As a Model for Central Macrophages in Erythroblastic Islands

MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia

MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia

UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia

MerTK-mediated engulfment of pyrenocytes by central macrophages in erythroblastic islands

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

A Small Molecule Inhibitor of the Gas6/Mer Pathway Inhibits Platelet Activation and Thrombosis with Equal Efficacy to, but Greater Potency Than, iMer, the Novel MerTK Splice Variant

A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia

A Distinct Expression of Various Gene Subsets in CD34+ Cells Obtained From Patients with Early and Advanced Myelodysplastic Syndrome.

A novel role for c-Src and STAT3 in apoptotic cell–mediated MerTK-dependent immunoregulation of dendritic cells

Synergistic Killing of E2A-PBX1 + B-ALL Cells by Chemotherapeutic Agents and MerTK Inhibition

Targeted Disruption of GAS6-Mertk Pathway Leads to Defects in Physiological Clearance of Expelled Nuclei from Erythroblasts by Bone Marrow Macrophages.

Apoptotic cells induce Mer tyrosine kinase–dependent blockade of NF-κB activation in dendritic cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only